
Meliora Therapeutics is a biotech company focused on revolutionizing oncology drug development through a machine learning-driven platform that identifies the true mechanisms of action of cancer therapies. By leveraging modern molecular fingerprinting and advanced computational techniques, Meliora aims to improve the accuracy and effectiveness of drug development, addressing the high failure rates in clinical testing. Their innovative approach allows for the identification of potent compounds that can inhibit key cancer targets, positioning them as a leader in precision oncology.

Meliora Therapeutics is a biotech company focused on revolutionizing oncology drug development through a machine learning-driven platform that identifies the true mechanisms of action of cancer therapies. By leveraging modern molecular fingerprinting and advanced computational techniques, Meliora aims to improve the accuracy and effectiveness of drug development, addressing the high failure rates in clinical testing. Their innovative approach allows for the identification of potent compounds that can inhibit key cancer targets, positioning them as a leader in precision oncology.
Headquarters: San Francisco, United States
Founded: 2021
Focus: Machine learning-driven mechanism-of-action deconvolution for oncology drug discovery
Employees: 8
Known funding: $11.0M seed (reported)
Oncology drug discovery and development; mechanism-of-action deconvolution
2021
Biotechnology
$11,000,000
Seed round with a syndicate of investors (reported total and lead investors listed).
“Syndicate includes institutional VCs and angel investors (e.g., ZhenFund, HOF Capital, Obvious Ventures, Village Global, others).”